(19)
(11) EP 4 770 678 A1

(12)

(43) Date of publication:
08.07.2026 Bulletin 2026/28

(21) Application number: 24765720.8

(22) Date of filing: 22.08.2024
(51) International Patent Classification (IPC): 
A61K 47/68(2017.01)
A61P 35/00(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 47/68035; A61K 47/6843; A61P 35/00; C07K 16/3092; C07K 2317/77; A61K 2039/507
(86) International application number:
PCT/GB2024/052205
(87) International publication number:
WO 2025/046218 (06.03.2025 Gazette 2025/10)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
GE KH MA MD TN

(30) Priority: 30.08.2023 GB 202313214

(71) Applicant: Iksuda Therapeutics Limited
Newcastle Upon Tyne NE4 5BX (GB)

(72) Inventors:
  • LODGE, Adam
    Stockton-on-Tees Cleveland TS16 0RP (GB)
  • DECKERT, Jutta
    Lexington, Massachusetts 02420 (US)
  • LUTZ, Robert
    Wayland, Massachusetts 01778 (US)
  • MYSLIWY, Justyna
    Newcastle upon Tyne Tyne and Wear NE5 3QU (GB)

(74) Representative: Murgitroyd & Company 
165-169 Scotland Street
Glasgow G5 8PL
Glasgow G5 8PL (GB)

   


(54) CO-ADMINISTRATION OF ANTIBODY-DRUG CONJUGATE